Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Charles S. Kuzma
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Related publications
P2-033Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Dose Dense in Stage III Breast Cancer
Annals of Oncology
Medicine
Oncology
Hematology
A Feasibility Study of Bevacizumab Plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Axillary Management of Stage II/III Breast Cancer in Patients Treated With Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)
Journal of the American College of Surgeons
Surgery
Fifteen-Year Median Follow-Up Results After Neoadjuvant Doxorubicin, Followed by Mastectomy, Followed by Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Followed by Radiation for Stage III Breast Cancer: A Phase II Trial (CALGB 8944)
Breast Cancer Research and Treatment
Cancer Research
Oncology
Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Nonamplified/Her2/Neu Negative/Polysomy 17 Absent Breast Cancer Patients
Cancer Management and Research
Oncology
Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer With Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)
Frontiers in Oncology
Cancer Research
Oncology
High Expression of Class III Β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Hormone Receptor-Negative as a Predictive Factor for Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer
Einstein (São Paulo, Brazil)
Medicine
